Objectives
- Describe the financial impact of HCV treatment
- Identify current restrictions to HCV treatment common among third party payers
- Illustrate successful navigation through the prior authorization and appeal process
- Review criteria and options for patient assistance programs (PAP)
Speaker
Autumn Bagwell PharmD BCPS
Browse more